Author: admin

Freelance develops a new product to diagnose and predict invasive tumors. -the new product has already been tested successfully in hospitals in Andalusia, Asturias, Cantabria, Cataluña, Galicia, Madrid, Navarre, Basque country and Valencia – allows to diagnose and predict the invasiveness of cancer of the pancreas, breast, lung, colon and head and neck, with levels of sensitivity and specificity over 90% -freelance has identified genes and proteins involved in the invasiveness of the tumor and It has developed monoclonal antibodies to detect them specifically Spain, March of 2013.- the freelance Spanish company has developed a new product for the diagnosis and prognosis of invasiveness of tumors of the pancreas, breast, lung, colon and head and neck. The new product has already been tested successfully in hospitals in Andalusia, Asturias, Navarra, Cantabria, Cataluña, Galicia, Madrid, Basque country and Valencia. Freelance has identified genes and proteins of peritumoral stroma, i.e. of mesenchymal cells and the extracellular matrix surrounding the tumor cells. The COL11A1 gene and the protein that encodes it, collagen XI-α1, are expressed in the stromal fibroblasts associated with invasive tumors, distinguishing them from non-invasive. In addition, this protein is involved in the alteration of the composition of the extracellular matrix that facilitates the invasiveness of the tumor. Freelance has developed and clinically validated a monoclonal antibody capable of detecting specifically XI-α1 collagen in tissues of patients with infiltrating carcinomas…...